"The goal of a CME AWAY® conference by Sea Courses is to provide the very best opportunity for health care professionals to not only LEARN but to CONNECT with peers in a stimulating yet RELAXING environment."
No upcoming CME conferences are listed at this time.
Dr. Goldstein attended the University of Miami’s Honor Program in Medical Education and completed his pediatric residency at the University of California, Los Angeles, and Neonatal-Perinatal Medicine fellowship at the University of California, Irvine. Dr. Goldstein is board certified in Pediatrics and Neonatal-Perinatal Medicine. He is a Professor of Pediatrics at Loma Linda University Children’s Hospital.
Dr. Goldstein is Editor-in-Chief of Neonatology Today (NeonatologyToday.net), the Chairman of Physicians Against Drugs Shortages (PADS) (www.physiciansagainstdrugshortages.com/), and Medical Director of the National Coalition for Infant Health (NCfIH) (www.infanthealth.org). He is also the National Chair of the American Academy of Pediatrics Multidisciplinary Action Group 2 Section Forum Management Committee and past president (aap.org) of the National Perinatal Association (NPA) (www.nationalperinatal.org).
Dr. Goldstein’s most important trait is his tireless devotion to patient access issues, and he has been a vocal advocate for “right” sizing technology. When his hospital and many others nationwide could not purchase medical devices vital to patient care, Dr. Goldstein wrote senators and members of Congress. He testified in front of a United States Senate Sub-Committee of the Judiciary regarding the practices of the Group Purchasing Organizations and the restriction of access to vital medical devices and pharmaceuticals. Dr. Goldstein’s vigilance in modifying these practices and improving patient access to medical supplies and pharmaceuticals made the front page of the New York Times and was featured on 60 minutes.
Dr. Goldstein advocates improving the physician-industry relationship as crucial in providing exceptional care. He supports transparency, dialog, and better engagement with industry to ensure that the most advanced pharmaceuticals and medical devices are developed and available for the most at-risk pediatric patients.
